



Willcox, A., Culliford, L., Ellis, L., Rogers, C. A., Cree, A., Chakravarthy, U., Ennis, S., Behar-Cohen, F., Reeves, B. C., Sivaprasad, S., & Lotery, A. (2019). Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial. *Eye*, 33(2), 295-303.
<https://doi.org/10.1038/s41433-018-0212-2>

Peer reviewed version

Link to published version (if available):
[10.1038/s41433-018-0212-2](https://doi.org/10.1038/s41433-018-0212-2)

[Link to publication record in Explore Bristol Research](#)
PDF-document

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Supplementary information 1.

Child-Pugh Class definitions

Measure	1 point	2 points	3 points
Total bilirubin (mg/dL)	<2	2-3	>3
Serum albumin (g/dL)	>3.5	2.8-3.5	<2.8
Prothrombin time, prolongation (s) OR International normalised ratio (INR)	<4.0 <1.7	4.0-6.0 1.7-2.2	> 6.0 >2.2
Ascites	None	Mild (medically controlled)	Moderate to Severe (poorly controlled)
Hepatic encephalopathy	None	Grade I-II (suppressed with medication/medically controlled)	Grade III-IV (refractory/poorly controlled)

Interpretation of Score

5-6 points = Class A

7-9 points = Class B

10-15 points = Class C*

*Class C is an exclusion criterion for the VICI trial.